KELVRI Trademark

Trademark Overview


On Monday, December 16, 2019, a trademark application was filed for KELVRI with the United States Patent and Trademark Office. The USPTO has given the KELVRI trademark a serial number of 88728518. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Tuesday, June 25, 2024. This trademark is owned by Teva Pharmaceuticals USA, Inc.. The KELVRI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ...
kelvri

General Information


Serial Number88728518
Word MarkKELVRI
Filing DateMonday, December 16, 2019
Status730 - FIRST EXTENSION - GRANTED
Status DateTuesday, June 25, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 7, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations for the treatment of neurological disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, December 19, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTeva Pharmaceuticals USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Party NameTeva Pharmaceuticals USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events


Event DateEvent Description
Thursday, December 19, 2019NEW APPLICATION ENTERED
Thursday, December 19, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, March 16, 2020ASSIGNED TO EXAMINER
Monday, March 16, 2020SUSPENSION LETTER WRITTEN
Monday, March 16, 2020LETTER OF SUSPENSION E-MAILED
Monday, March 16, 2020NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Monday, September 21, 2020REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Sunday, March 21, 2021REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Thursday, September 23, 2021REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Wednesday, March 23, 2022REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Sunday, October 2, 2022REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Sunday, April 2, 2023REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Thursday, October 5, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 18, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 7, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 25, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, June 25, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 25, 2024SOU EXTENSION 1 FILED
Tuesday, June 25, 2024SOU EXTENSION 1 GRANTED
Tuesday, November 7, 2023PUBLISHED FOR OPPOSITION
Tuesday, January 2, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT